Hera Biotech

About This Project

Hera Biotech Is Developing and Commercializing The World’s 1st Non-Surgical Test For Definitive Diagnosis And Staging Of Endometriosis. Hera’s initial goal is to commercialize the MetriDx™, a novel, non-surgical method for the definitive and early diagnosis of endometriosis. Endometriosis is defined as the presence of endometrial glands and stromal-like lesions outside of the uterus. Endometriosis affects 10-20% of all women of reproductive age; 7-13 million in the US alone. Current diagnosis of endometriosis is by visualization during laparoscopic surgery, confirmed by histological pathology, performed under general anesthesia by a surgeon or gynecologist. The VentureDNA team is providing advisory services to senior management, while opening access to its worldwide network of marketing and medical professionals. Please visit: Hera Biotech 

Advisory Services